CD307C抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD307C mouse mAb (green) and negative control (red).    

  
  

CD307c antibody targets the CD307c antigen, also known as FCRL3 (Fc receptor-like 3), a member of the Fc receptor-like (FCRL) family expressed primarily on B lymphocytes. FCRL proteins share structural homology with classical Fc receptors but lack binding affinity for immunoglobulins. CD307c is characterized by extracellular immunoglobulin-like domains and cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or activating motifs (ITAMs), enabling modulation of B-cell receptor (BCR) signaling. It plays dual roles in immune regulation, either dampening or enhancing B-cell activation depending on cellular context and ligand interactions.

Research highlights CD307c's association with autoimmune diseases and malignancies. Genetic polymorphisms in *FCRL3* are linked to increased susceptibility to rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune thyroid disorders, suggesting its role in immune tolerance. In B-cell cancers, CD307c is overexpressed in chronic lymphocytic leukemia (CLL) and certain lymphomas, positioning it as a potential diagnostic marker or therapeutic target.

CD307c antibodies are valuable tools for studying B-cell biology, dissecting FCRL3 signaling pathways, and exploring therapeutic applications. Neutralizing antibodies may suppress pathogenic B-cell activity in autoimmunity, while antibody-drug conjugates (ADCs) or bispecific antibodies are under investigation for targeting CD307c-positive malignancies. Ongoing studies aim to clarify its ligand interactions and tissue-specific functions, with implications for precision immunotherapy.